Author:
Azar Joseph,Kaddoura Tala,Timonian Michael Anthony,Karam Elsa Salim,Abou-Kheir Wassim,Daoud Georges
Funder
American University of Beirut Faculty of Medicine
Reference88 articles.
1. BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients;AbdelHamid;Clin. Chim. Acta,2021
2. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women;Abeliovich;Am. J. Hum. Genet.,1997
3. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer;Abou-Zeid;Scand. J. Clin. Lab. Invest.,2011
4. PIK3CA alterations in Middle Eastern ovarian cancers;Abubaker;Mol. Cancer,2009
5. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan;Abu-Helalah;Sci. Rep.,2020